source
- Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trialKallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…
- FAIR Act could boost U.S. rare‑disease trial access and restore biotech leadershipIn a recent BioSpace podcast, host Jennifer C. Smith‑Parker talked with Max Bronstein of Aviva Strategies and Teresa Barnes of PF Warriors about a growing problem: U.S. patients are increasingly un…